FDA approves asundexian, the first factor XIa inhibitor for stroke prevention
On November 9, the FDA approved Sunharbo (asundexian) 50 mg tablets from Bayer, the first factor XIa inhibitor. It is used with antiplatelet therapy to lower stroke risk after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk TIA. In the phase 3 OCEANIC-STROKE trial of 12,327 adults, it cut ischemic stroke risk by 26% versus placebo. Overall major bleeding was similar, but higher in patients over 75 and in the first 90 days.
For pharmacology students, this is a brand-new drug class aimed at a new target in the coagulation cascade, plus a live lesson in interactions: combined P-gp and strong CYP3A4 inducers such as carbamazepine are not recommended because they may reduce its effect.
Do you think factor XIa inhibitors will change how we balance clot prevention against bleeding risk?

0 Comments
Sign in to join the discussion
No comments yet. Be the first to comment!